健民集团(600976.SH)：鼻渊通窍颗粒获得药物临床试验批准通知书

Core Viewpoint - Jianmin Group (600976.SH) has received the Clinical Trial Approval Notice for the nasal medication "Biyuan Tongqiao Granules" from the National Medical Products Administration, indicating a significant step in the development of this traditional Chinese medicine [1] Group 1 - The product "Biyuan Tongqiao Granules" is a traditional Chinese medicine that has already been marketed [1] - The primary function of the granules is to dispel wind and clear heat, as well as to promote lung function and open nasal passages [1] - The medication is indicated for acute nasal inflammation (acute sinusitis) associated with external pathogens affecting the lungs, with symptoms including pressure pain in the forehead or cheekbones, nasal congestion, and other related symptoms [1]